Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 100

1.

Pancreatitis in patients treated with brentuximab vedotin: a previously unrecognized serious adverse event.

Gandhi MD, Evens AM, Fenske TS, Hamlin P, Coiffier B, Engert A, Moskowitz AJ, Ghosh N, Petrich AM, Lomasney J, Chadburn A, Wood GS, Salva K, Nardone B, Trifilio SM, Raisch DW, West DP, Gordon LI, Winter JN.

Blood. 2014 May 1;123(18):2895-7. doi: 10.1182/blood-2014-03-561878. No abstract available.

PMID:
24786458
[PubMed - indexed for MEDLINE]
2.

Brentuximab vedotin in heavily treated Hodgkin and anaplastic large-cell lymphoma, a single centre study on 45 patients.

Monjanel H, Deville L, Ram-Wolff C, Venon MD, Franchi P, Benet C, de Kerviler E, Malphettes M, Thieblemont C, Brice P.

Br J Haematol. 2014 Jul;166(2):306-8. doi: 10.1111/bjh.12849. Epub 2014 Mar 27. No abstract available.

PMID:
24673542
[PubMed - indexed for MEDLINE]
3.

Brentuximab vedotin: a review of its use in patients with hodgkin lymphoma and systemic anaplastic large cell lymphoma following previous treatment failure.

Garnock-Jones KP.

Drugs. 2013 Mar;73(4):371-81. doi: 10.1007/s40265-013-0031-5. Review.

PMID:
23494187
[PubMed - indexed for MEDLINE]
4.

Brentuximab vedotin: its role in the treatment of anaplastic large cell and Hodgkin's lymphoma.

Haddley K.

Drugs Today (Barc). 2012 Apr;48(4):259-70. doi: 10.1358/dot.2012.48.4.1788435. Review.

PMID:
22536568
[PubMed - indexed for MEDLINE]
5.

Severe peripheral motor neuropathy in a patient with Hodgkin lymphoma treated with brentuximab vedotin.

Pastorelli F, Derenzini E, Plasmati R, Pellegrini C, Broccoli A, Casadei B, Argnani L, Salvi F, Pileri S, Zinzani PL.

Leuk Lymphoma. 2013 Oct;54(10):2318-21. doi: 10.3109/10428194.2013.773997. Epub 2013 Mar 8. No abstract available.

PMID:
23391144
[PubMed - indexed for MEDLINE]
6.

Brentuximab vedotin for the treatment of CD30+ lymphomas.

Foyil KV, Bartlett NL.

Immunotherapy. 2011 Apr;3(4):475-85. doi: 10.2217/imt.11.15. Review.

PMID:
21463188
[PubMed - indexed for MEDLINE]
7.

Brentuximab vedotin does not cause clinically relevant QTc interval prolongation in patients with CD30-positive hematologic malignancies.

Han TH, Chen R, Advani R, Berryman RB, Smith SE, Forero-Torres A, Rosenblatt JD, Smith MR, Zain J, Hunder NN, Engert A.

Cancer Chemother Pharmacol. 2013 Jul;72(1):241-9. doi: 10.1007/s00280-013-2192-z. Epub 2013 May 30.

PMID:
23719719
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

U.S. Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma.

de Claro RA, McGinn K, Kwitkowski V, Bullock J, Khandelwal A, Habtemariam B, Ouyang Y, Saber H, Lee K, Koti K, Rothmann M, Shapiro M, Borrego F, Clouse K, Chen XH, Brown J, Akinsanya L, Kane R, Kaminskas E, Farrell A, Pazdur R.

Clin Cancer Res. 2012 Nov 1;18(21):5845-9. doi: 10.1158/1078-0432.CCR-12-1803. Epub 2012 Sep 7.

PMID:
22962441
[PubMed - indexed for MEDLINE]
Free Article
9.

Brentuximab vedotin: a new age in the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma.

Minich SS.

Ann Pharmacother. 2012 Mar;46(3):377-83. doi: 10.1345/aph.1Q680. Epub 2012 Mar 6. Review.

PMID:
22395252
[PubMed - indexed for MEDLINE]
10.

Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study.

Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, Matous J, Ramchandren R, Fanale M, Connors JM, Yang Y, Sievers EL, Kennedy DA, Shustov A.

J Clin Oncol. 2012 Jun 20;30(18):2190-6. doi: 10.1200/JCO.2011.38.0402. Epub 2012 May 21.

PMID:
22614995
[PubMed - indexed for MEDLINE]
Free Article
11.

Brentuximab vedotin in anaplastic large cell lymphoma.

Skarbnik AP, Smith MR.

Expert Opin Biol Ther. 2012 May;12(5):633-9. doi: 10.1517/14712598.2012.673578. Epub 2012 Mar 27.

PMID:
22449148
[PubMed - indexed for MEDLINE]
12.

Brentuximab vedotin.

Deng C, Pan B, O'Connor OA.

Clin Cancer Res. 2013 Jan 1;19(1):22-7. doi: 10.1158/1078-0432.CCR-12-0290. Epub 2012 Nov 15. Review.

PMID:
23155186
[PubMed - indexed for MEDLINE]
Free Article
13.

Brentuximab vedotin.

[No authors listed]

Drugs R D. 2011;11(1):85-95. doi: 10.2165/11591070-000000000-00000. Review.

PMID:
21410298
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Brentuximab Vedotin (SGN-35), an antibody-drug conjugate for the treatment of CD30-positive malignancies.

Gualberto A.

Expert Opin Investig Drugs. 2012 Feb;21(2):205-16. doi: 10.1517/13543784.2011.641532. Epub 2011 Nov 30. Review.

PMID:
22127011
[PubMed - indexed for MEDLINE]
15.

Clinical binding properties, internalization kinetics, and clinicopathologic activity of brentuximab vedotin: an antibody-drug conjugate for CD30-positive lymphoid neoplasms.

Fromm JR, McEarchern JA, Kennedy D, Thomas A, Shustov AR, Gopal AK.

Clin Lymphoma Myeloma Leuk. 2012 Aug;12(4):280-3. doi: 10.1016/j.clml.2012.01.012. Epub 2012 Apr 26. No abstract available.

PMID:
22542449
[PubMed - indexed for MEDLINE]
16.

Brentuximab vedotin: an anti-CD30 antibody-drug conjugate.

Bradley AM, Devine M, DeRemer D.

Am J Health Syst Pharm. 2013 Apr 1;70(7):589-97. doi: 10.2146/ajhp110608. Review.

PMID:
23515511
[PubMed - indexed for MEDLINE]
17.

[Brentuximab vedotin: new treatment for CD30+ lymphomas].

Terriou L, Bonnet S, Debarri H, Demarquette H, Morschhauser F.

Bull Cancer. 2013 Jul-Aug;100(7-8):775-9. doi: 10.1684/bdc.2013.1778. Review. French.

PMID:
23831822
[PubMed - indexed for MEDLINE]
18.

Brentuximab vedotin for the treatment of patients with Hodgkin lymphoma.

Younes A.

Hematol Oncol Clin North Am. 2014 Feb;28(1):27-32. doi: 10.1016/j.hoc.2013.10.005. Review.

PMID:
24287065
[PubMed - indexed for MEDLINE]
19.

Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma.

Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Ramchandren R, Bartlett NL, Cheson BD, de Vos S, Forero-Torres A, Moskowitz CH, Connors JM, Engert A, Larsen EK, Kennedy DA, Sievers EL, Chen R.

J Clin Oncol. 2012 Jun 20;30(18):2183-9. doi: 10.1200/JCO.2011.38.0410. Epub 2012 Mar 26.

PMID:
22454421
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

FDA approves brentuximab vedotin for Hodgkin lymphoma and systemic anaplastic large-cell lymphoma.

[No authors listed]

Oncology (Williston Park). 2011 Sep;25(10):904. No abstract available.

PMID:
22010386
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk